| All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy |
Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-13 17:01:01 |
Czytaj oryginał (ang.) |
| Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates |
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago. |
zacks.com |
2025-05-12 22:51:07 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade |
The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-08 15:02:01 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 164,500 shares of common stock to nine new employees under the Company's 2024 Induceme. |
businesswire.com |
2025-05-02 20:01:00 |
Czytaj oryginał (ang.) |
| Immunome: Transformed Pipeline Offers Multiple Catalysts |
Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The company's strong financial position, with a cash runway extending through 2027, supports ongoing clinical development and potential market entry for key assets. Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts. |
seekingalpha.com |
2025-04-17 10:06:52 |
Czytaj oryginał (ang.) |
| Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at ww. |
businesswire.com |
2025-04-04 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company's 2024 Induce. |
businesswire.com |
2025-04-03 20:05:00 |
Czytaj oryginał (ang.) |
| Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates |
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2025-03-19 20:35:23 |
Czytaj oryginał (ang.) |
| Immunome Reports Full Year 2024 Financial Results and Provides Business Update |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. “Immunome's efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We are pleased with the progress of our pipeline and, with multiple. |
businesswire.com |
2025-03-19 18:05:00 |
Czytaj oryginał (ang.) |
| Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. “Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients,” said Bob Lechleider, M.D., Chief Medical Officer at Immunome. “The dosing of our first patient with IM-1021. |
businesswire.com |
2025-03-10 09:41:00 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 49,000 shares of common stock to four new employees under the Company's 2024 Inducem. |
businesswire.com |
2025-03-06 18:01:00 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 51,000 shares of common stock to four new employees under the Company's 2024 Indu. |
businesswire.com |
2025-02-06 18:01:00 |
Czytaj oryginał (ang.) |
| Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, befo. |
businesswire.com |
2025-01-31 18:01:00 |
Czytaj oryginał (ang.) |
| Immunome Can Take The Fight To Competitors With Varegacestat |
Immunome Can Take The Fight To Competitors With Varegacestat |
seekingalpha.com |
2025-01-30 12:27:41 |
Czytaj oryginał (ang.) |
| Immunome Announces Pricing of Upsized Public Offering of Common Stock |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering ex. |
businesswire.com |
2025-01-30 01:11:00 |
Czytaj oryginał (ang.) |
| Immunome Announces Proposed Public Offering of Common Stock |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $125.0 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-da. |
businesswire.com |
2025-01-29 18:27:00 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 45,000 shares of common stock to four new employees under the Company's 2024 Induc. |
businesswire.com |
2025-01-02 20:03:00 |
Czytaj oryginał (ang.) |
| 3 Small-Cap Stocks With Big Growth Potential |
According to several indicators—including a robust labor market and tamed inflation figures—the U.S. economy heads into 2025 with strong tailwinds. Many of the securities that have been primary beneficiaries of this economic well-being are large-cap (or even mega-cap) titans in the tech industry. |
marketbeat.com |
2024-12-13 09:01:43 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 210,500 shares of common stock to 15 new employees under the Company's 2024 Inducement Plan. The. |
businesswire.com |
2024-12-02 20:26:00 |
Czytaj oryginał (ang.) |
| Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome's management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at ww. |
businesswire.com |
2024-11-27 10:00:00 |
Czytaj oryginał (ang.) |
| Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates |
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago. |
zacks.com |
2024-11-13 20:16:08 |
Czytaj oryginał (ang.) |
| Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section o. |
businesswire.com |
2024-11-05 10:00:00 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The. |
businesswire.com |
2024-11-01 18:05:00 |
Czytaj oryginał (ang.) |
| Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled “Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload” at the 36th EORTC-NCI-AACR Symposium on Molecular Tar. |
businesswire.com |
2024-10-29 10:00:00 |
Czytaj oryginał (ang.) |
| Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024. Immunome expects to submit an IND for the IM-1021 program to the FDA in. |
businesswire.com |
2024-10-18 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 3, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 851,400 shares of common stock to 25 new employees under the Company's 2024 Inducement Plan. The Co. |
businesswire.com |
2024-10-08 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations. |
businesswire.com |
2024-08-29 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates |
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.46 per share a year ago. |
zacks.com |
2024-08-12 22:15:43 |
Czytaj oryginał (ang.) |
| Immunome: AL102 And Other Established Protein Targets Could Drive Value |
Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025. |
seekingalpha.com |
2024-06-27 18:14:36 |
Czytaj oryginał (ang.) |
| Immunome Announces Completion of Purchase of Assets from Atreca |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 million upfront, and Atreca will be eligible for up to $7.0 million in clinical development milestones. Immunome received the rights to 28 antibodies as well as certain ma. |
businesswire.com |
2024-05-20 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome Announces Promotion of Max Rosett to Chief Financial Officer |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome's Interim Chief Financial Officer since January 2024. “Max has been instrumental in Immunome's rapid transformation over the. |
businesswire.com |
2024-05-17 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates |
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2024-05-14 14:11:05 |
Czytaj oryginał (ang.) |
| Immunome Reports First Quarter 2024 Financial Results and Provides Business Update |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. “Immunome continues to build momentum. We have completed the integration of AL102 and are executing activities necessary for regulatory submissions,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “. |
businesswire.com |
2024-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome to Present at 2024 Bank of America Healthcare Conference |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's websit. |
businesswire.com |
2024-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Immunome Appoints Kinney Horn as Chief Business Officer |
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy. “Immunome is excited to welcome Kinney to our executive team as we advance our broad pipeline of target. |
businesswire.com |
2024-05-02 12:00:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for |
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-04-26 15:05:44 |
Czytaj oryginał (ang.) |